Di-Thioester Cationic Lipids for In Vivo mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nucleic acid delivery methods, particularly for mRNA therapy, face challenges in achieving effective in vivo delivery while maintaining a favorable toxicity profile.
Innovation Solution
Development of a novel class of di-thioester cationic lipid compounds with specific structures and properties for encapsulating nucleic acids, which form liposomes for enhanced delivery and expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing nucleic acid delivery methods are used, then delivery can be achieved, but toxicity is high and delivery effectiveness is insufficient
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by introducing di-thioester linkages and specific headgroup configurations (Formula A and B structures). These parameter changes in molecular structure result in lipids that maintain effective nucleic acid delivery while reducing cytotoxicity compared to conventional cationic lipids. The specific chain lengths, headgroup compositions, and ester linkage types are optimized parameters that resolve the contradiction between delivery effectiveness and toxicity.
Solution Approach 2:
The invention creates composite lipid structures combining di-thioester linkages with specific headgroups (such as choline, ethanolamine, or serine derivatives) and hydrocarbon chains. These composite molecular structures achieve synergistic effects where the di-thioester portion enables effective nucleic acid complexation and delivery, while the specific headgroup and chain composition reduces toxic effects on cells.
2Productivity
If delivery effectiveness is increased, then protein production improves, but maintaining favorable toxicity becomes more difficult
Solution Approach 1:
The patent optimizes specific molecular parameters including the di-thioester linkage stability, headgroup charge density, and hydrocarbon chain length to achieve high protein production from delivered nucleic acids while maintaining favorable toxicity profiles. The structural parameters in Formula A and B are specifically tuned to balance transfection efficiency with cellular safety.
Data Source
AI summary
The present invention provides, in part, di-thioester cationic lipid compounds or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.